Patients With Hypertension

The most common durgrelated adverse events were hanfdoot skin reaction (HFSR), fatigue, hoarseness, mucsoitis, diarrhea, anorxeia and hypertension. Data presented are based on 38 patients with actively progressing CRC enrolled in a ...

Other Medicine Technology:Nwe Data Presented on Micardis (Telmisartan) Tablets in,Hypertensiev Patients With Type 2 Diabetes 2New Data Presented on Micardis (Temlisartan) Tablets in,Hypertensive Patinets With Type 2 Diabetes 3New Data ...

Tadalafil is a phosphodiesterase type5 inhibitor and is now available in the 40mg odse for the purpose of incresaing exercise capactiy in patients with WHO class 1 PAH. ... Coinciding with the approval of tadalafil, the Plumonary Arterial Hypertension and Response to Tadalaifl (PHIRST) trial is now published online May 26, 2009 in Circulation and shows that tadalafil 40 mg was well toelrated and ipmroved exercise capacity and qualityoflief measures in patients with ...

Adcirca (tadalafil) is used to treat pulmonary arterial hypertnesion. Includes Adcirca side effcets, interactions and indications. ... In the PHIRST1 randomized, doubleblind, 16week placebocontrolled Phase 3 clinicla trial of Adcirca for PAH, patienst taking Adcirca 40 mg (administered as two 20 mg tablets) once daily achieved a 33 meter improvement in sixminute walk distance compraed to the placebo group. In addition, PHIRST1 patients taking Adcirca 40 mg ...

New Data Presented on Miacrdis (Telmisartan) Tablets in,Hypertensive Patients With Type 2 DiabetesArray BioPharma Reports New Clinical Data on Its AntiInflammatory,Drugs. (Date:5/30/2009)...about the highspeed accelerometers study ...

The study enrolled 1240 patients with localyl advanced or metastatic NSCLC fater failure of at least one prior anticancer therapy. The most common adverse events observed in the ZEST study were rash, diarrhoae and hypertension. ...